Selected article for: "acute rejection and logistic regression"

Author: Vinson, Amanda J.; Agarwal, Gaurav; Dai, Ran; Anzalone, Alfred J.; Lee, Stephen B.; French, Evan; Olex, Amy; Madhira, Vithal; Mannon, Roslyn B.
Title: COVID-19 in Solid Organ Transplantation: Results of the National COVID Cohort Collaborative
  • Cord-id: uothm9vx
  • Document date: 2021_10_6
  • ID: uothm9vx
    Snippet: Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality in solid organ transplant (SOT) recipients. The National COVID Cohort Collaborative was developed to facilitate analysis of patient-level data for those tested for COVID-19 across the United States. METHODS. In this study, we identified a cohort of SOT recipients testing positive or negative for COVID-19 (COVID+ and COVID−, respectively) between January 1, 2020, and November 20, 2020. Univariable and multiv
    Document: Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality in solid organ transplant (SOT) recipients. The National COVID Cohort Collaborative was developed to facilitate analysis of patient-level data for those tested for COVID-19 across the United States. METHODS. In this study, we identified a cohort of SOT recipients testing positive or negative for COVID-19 (COVID+ and COVID−, respectively) between January 1, 2020, and November 20, 2020. Univariable and multivariable logistic regression were used to determine predictors of a positive result among those tested. Outcomes following COVID-19 diagnosis were also explored. RESULTS. Of 18 121 SOT patients tested, 1925 were positive (10.6%). COVID+ SOT patients were more likely to have a kidney transplant and be non-White race. Comorbidities were common in all SOT patients but significantly more common in those who were COVID+. Of COVID+ SOT, 42.9% required hospital admission. COVID+ status was the strongest predictor of acute kidney injury (AKI), rejection, and graft failure in the 90 d after testing. A total of 40.9% of COVID+ SOT experienced a major adverse renal or cardiac event, 16.3% experienced a major adverse cardiac event, 35.3% experienced AKI, and 1.5% experienced graft loss. CONCLUSIONS. In the largest US cohort of COVID+ SOT recipients to date, we identified patient factors associated with the diagnosis of COVID-19 and outcomes following infection, including a high incidence of major adverse renal or cardiac event and AKI.

    Search related documents:
    Co phrase search for related documents
    • academic medical center and acute myocardial infarction: 1
    • academic medical center and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • academic medical center and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • academic medical center and liver disease: 1, 2
    • academic medical center and liver diseases: 1
    • acquire high risk and acute respiratory syndrome: 1
    • acquire increase risk and acute respiratory syndrome: 1
    • acute aki kidney injury and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute myocardial infarction and liver disease: 1, 2, 3, 4, 5, 6
    • acute rejection and liver disease: 1, 2, 3, 4
    • acute rejection and liver diseases: 1, 2
    • acute respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and liver diseases: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adjustment variable: 1
    • acute respiratory syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver disease comorbidity: 1
    • acute respiratory syndrome and liver diseases: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25